Latest & greatest articles for pregabalin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on pregabalin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on pregabalin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for pregabalin

41. The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials

The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials Zaccara G, Gangemi P, Perucca P, Specchio L CRD summary The review concluded that individuals starting pregabalin treatment were at increased risk of several adverse (...) events, particularly those affecting cognition/co-ordination, which followed a dose-response relationship. The review was generally well conducted, but the potential issues with trial quality and the small number of trials for some adverse events limit the reliability of the results. Authors' objectives To determine the adverse event profile of pregabalin. Searching MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials (CENTRAL) were searched to February 2010. Search terms were

DARE.2012

42. Can pregabalin effectively diminish acute herpetic pain and reduce the incidence of post-herpetic neuralgia in patients who present with acute herpes zoster?

Can pregabalin effectively diminish acute herpetic pain and reduce the incidence of post-herpetic neuralgia in patients who present with acute herpes zoster? BestBets: Can pregabalin effectively diminish acute herpetic pain and reduce the incidence of post-herpetic neuralgia in patients who present with acute herpes zoster? Can pregabalin effectively diminish acute herpetic pain and reduce the incidence of post-herpetic neuralgia in patients who present with acute herpes zoster? Report (...) By: Eliane Raymond-Dufresne - PGY-3, Emergency Medicine Search checked by Katharine Wylie - Senior Informatacist Institution: Laval University, Qu�bec, Canada Date Submitted: 23rd November 2011 Date Completed: 13th February 2012 Last Modified: 20th February 2012 Status: Green (complete) Three Part Question In [patients with new onset of herpes zoster infection], can [pregabalin] be used to [decrease the incidence of post-herpetic neuralgia and to decrease the intensity of acute herpetic pain]? Clinical

BestBETS2012

43. Pregabalin reduces pain in patients with chronic pancreatitis in a randomized, controlled trial

Pregabalin reduces pain in patients with chronic pancreatitis in a randomized, controlled trial 21683078 2011 08 08 2011 10 13 2015 11 19 1528-0012 141 2 2011 Aug Gastroenterology Gastroenterology Pregabalin reduces pain in patients with chronic pancreatitis in a randomized, controlled trial. 536-43 10.1053/j.gastro.2011.04.003 Pain is a disabling symptom for patients with chronic pancreatitis (CP) and difficult to treat. Evidence from basic science and human studies indicates that pain (...) processing by the central nervous system is abnormal and resembles that observed in patients with neuropathic pain disorders. We investigated whether agents used to treat patients with neuropathic pain are effective in CP. We conducted a randomized, double-blind, placebo-controlled trial to evaluate the effects of the gabapentoid pregabalin as an adjuvant analgesic. We measured pain relief, health status, quality of life, and tolerability in 64 patients with pain from CP; they were randomly assigned

EvidenceUpdates2011

44. Safety and efficacy of pregabalin in patients with central post-stroke pain.

Safety and efficacy of pregabalin in patients with central post-stroke pain. 21316855 2011 04 18 2011 08 23 2015 11 19 1872-6623 152 5 2011 May Pain Pain Safety and efficacy of pregabalin in patients with central post-stroke pain. 1018-23 10.1016/j.pain.2010.12.023 Pregabalin has demonstrated efficacy in several forms of neuropathic pain, but its long-term efficacy in central post-stroke pain (CPSP) is unproven. We evaluated the efficacy and safety of pregabalin versus placebo in patients (...) with CPSP. A 13-week, randomized, double-blind, multicenter, placebo-controlled, parallel group study of 150 to 600 mg/day pregabalin was conducted in patients aged ≥18 years with CPSP. The primary efficacy endpoint was the mean pain score on the Daily Pain Rating Scale over the last 7 days on study drug up to week 12 or early termination visit. Secondary endpoints included other pain parameters and patient-reported sleep and health-related quality-of-life measures. A total of 219 patients were treated

EvidenceUpdates2011

45. Pregabalin for peripheral neuropathic pain: a multicenter, enriched enrollment randomized withdrawal placebo-controlled trial

Pregabalin for peripheral neuropathic pain: a multicenter, enriched enrollment randomized withdrawal placebo-controlled trial 21178603 2011 02 09 2011 06 02 2015 11 19 1536-5409 27 3 2011 Mar-Apr The Clinical journal of pain Clin J Pain Pregabalin for peripheral neuropathic pain: a multicenter, enriched enrollment randomized withdrawal placebo-controlled trial. 185-93 10.1097/AJP.0b013e3181fe13f6 To date, published neuropathic pain randomized controlled trials of pregabalin have involved (...) primarily diabetic peripheral neuropathy (DPN) and postherpetic neuralgia (PHN). This multicenter trial evaluated pregabalin in a broader range of neuropathic pain etiologies. In this enriched enrollment randomized withdrawal trial, 256 patients received single blind, flexible dose pregabalin for 4 weeks; stable concomitant analgesics were allowed. One hundred sixty-five (65%) had a ≥30% pain improvement and 157 were randomized and treated, double blind, to either continue pregabalin (n=80

EvidenceUpdates2011

46. Effective Dose of Peri-operative Oral Pregabalin as an Adjunct to Multimodal Analgesic Regimen in Lumbar Spinal Fusion Surgery

Effective Dose of Peri-operative Oral Pregabalin as an Adjunct to Multimodal Analgesic Regimen in Lumbar Spinal Fusion Surgery 21372654 2011 03 04 2011 07 22 2015 11 19 1528-1159 36 6 2011 Mar 15 Spine Spine Effective dose of peri-operative oral pregabalin as an adjunct to multimodal analgesic regimen in lumbar spinal fusion surgery. 428-33 10.1097/BRS.0b013e3181d26708 A prospective, randomized, controlled, and double-blind trial. To evaluate the effects of 2 different doses of perioperative (...) pregabalin administration, twice on the day of surgery, on acute postoperative pain after spinal surgery. Besides its well-established role on neuropathic pain, pregabalin seems to be a promising adjunct to multimodal analgesic regimen following surgery. No comprehensive data exist regarding the optimal dosage of pregabalin on reducing postoperative pain and opioid consumption in spinal surgery. Patients were randomly assigned to 1 of 3 groups. The placebo group (n = 28) received placebo capsules 1 hour

EvidenceUpdates2011

47. A meta-analysis of the efficacy of pregabalin in the treatment of generalized anxiety disorder

A meta-analysis of the efficacy of pregabalin in the treatment of generalized anxiety disorder A meta-analysis of the efficacy of pregabalin in the treatment of generalized anxiety disorder A meta-analysis of the efficacy of pregabalin in the treatment of generalized anxiety disorder Boschen MJ CRD summary The review concluded that pregabalin was an effective treatment for generalised anxiety disorder compared to placebo. Given limitations in the review process as well as uncertain quality (...) of the included trials the authors conclusion may not be reliable. Authors' objectives To determine the efficacy of pregabalin for treatment of generalised anxiety disorder. Searching PubMed was searched up to December 2010 for relevant published peer-reviewed trials. Search terms were reported. References lists were searched. Study selection Randomised controlled trials (RCTs) that compared pregabalin with placebo for treatment of primary generalised anxiety disorder were eligible for inclusion in the review

DARE.2011

48. The efficacy and safety of pregabalin in the treatment of neuropathic pain associated with chronic lumbosacral radiculopathy

The efficacy and safety of pregabalin in the treatment of neuropathic pain associated with chronic lumbosacral radiculopathy 20493632 2010 08 13 2010 12 06 2015 11 19 1872-6623 150 3 2010 Sep Pain Pain The efficacy and safety of pregabalin in the treatment of neuropathic pain associated with chronic lumbosacral radiculopathy. 420-7 10.1016/j.pain.2010.04.013 We evaluated the efficacy of pregabalin in patients with chronic lumbosacral radiculopathy. This randomized, controlled, withdrawal trial (...) included five phases: screening (4-18 days); run-in (4-10 days) to screen out placebo responders; single-blind (28 days) to identify pregabalin responders; double-blind to randomize responders to pregabalin or placebo (35 days); and final study medication taper (7 days). The primary endpoint was time to loss of response (LOR) during the double-blind phase (1-point increase in pain, discontinuation, or rescue-medication use). In the single-blind phase, 58% of patients had 30% pain reduction

EvidenceUpdates2010

49. Pregabalin for the treatment of men with chronic prostatitis/chronic pelvic pain syndrome: a randomized controlled trial

Pregabalin for the treatment of men with chronic prostatitis/chronic pelvic pain syndrome: a randomized controlled trial 20876412 2010 09 29 2010 10 28 2016 12 15 1538-3679 170 17 2010 Sep 27 Archives of internal medicine Arch. Intern. Med. Pregabalin for the treatment of men with chronic prostatitis/chronic pelvic pain syndrome: a randomized controlled trial. 1586-93 10.1001/archinternmed.2010.319 Evidence suggests that the urogenital pain of chronic prostatitis/chronic pelvic pain syndrome (...) (CP/CPPS) may be neuropathic. This randomized, double-blind, placebo-controlled trial was conducted across 10 tertiary care centers in North America to determine whether pregabalin, which has been proved effective in other chronic pain syndromes, is effective in reducing CP/CPPS symptoms. In 2006-2007, 324 men with pelvic pain for at least 3 of the previous 6 months were enrolled in this study. Men were randomly assigned to receive pregabalin or placebo in a 2:1 ratio and were treated for 6 weeks

EvidenceUpdates2010 Full Text: Link to full Text with Trip Pro

50. A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin

A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin 19962354 2010 05 04 2010 08 17 2015 11 19 1528-8447 11 5 2010 May The journal of pain : official journal of the American Pain Society J Pain A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin. 462-71 10.1016/j.jpain.2009.09.003 The aim (...) of this randomized double-blind, placebo-controlled, parallel-group study was to evaluate the efficacy, safety, and tolerability of pregabalin in combination with oxycodone or placebo, in patients with either postherpetic neuralgia (PHN) or painful diabetic neuropathy (PDN). After a 7-day washout period, 62 patients were randomized to receive either oxycodone mixture 10 mg/day or placebo mixture for 1 week. Patients were then started on open-label pregabalin (75, 150, 300 and 600 mg/day) according to a forced

EvidenceUpdates2010

51. Perioperative oral pregabalin reduces chronic pain after total knee arthroplasty: a prospective, randomized, controlled trial

Perioperative oral pregabalin reduces chronic pain after total knee arthroplasty: a prospective, randomized, controlled trial 19910619 2009 12 21 2010 01 12 2015 11 19 1526-7598 110 1 2010 Jan 01 Anesthesia and analgesia Anesth. Analg. Perioperative oral pregabalin reduces chronic pain after total knee arthroplasty: a prospective, randomized, controlled trial. 199-207 10.1213/ANE.0b013e3181c4273a Despite the enormous success of total knee arthroplasty (TKA), chronic neuropathic pain can develop (...) postoperatively and is both distressing and difficult to treat once established. We hypothesized that perioperative treatment with pregabalin, a chronic pain medication, would reduce the incidence of postsurgical neuropathic pain. We performed a randomized, placebo-controlled, double-blind trial of pregabalin (300 mg) administered before TKA and for 14 days after TKA (150-50 mg twice daily). Patients were screened for the presence of neuropathic pain at 3 and 6 mo postoperatively using the Leeds Assessment

EvidenceUpdates2010

52. Randomised controlled trial: Pregabalin similar to lorazepam for alcohol withdrawal symptoms

Randomised controlled trial: Pregabalin similar to lorazepam for alcohol withdrawal symptoms Pregabalin similar to lorazepam for alcohol withdrawal symptoms | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log (...) in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Pregabalin similar to lorazepam for alcohol withdrawal symptoms Article Text Therapeutics Randomised controlled trial Pregabalin similar to lorazepam for alcohol withdrawal symptoms Giovanni Addolorato 1 , Lorenzo Leggio 1 , 2 Statistics from Altmetric.com No Altmetric data available for this article. Commentary on: Martinotti G , di Nicola M

Evidence-Based Medicine (Requires free registration)2010

53. Gabapentin and pregabalin in the treatment of fibromyalgia: a systematic review and a meta-analysis

Gabapentin and pregabalin in the treatment of fibromyalgia: a systematic review and a meta-analysis Gabapentin and pregabalin in the treatment of fibromyalgia: a systematic review and a meta-analysis Gabapentin and pregabalin in the treatment of fibromyalgia: a systematic review and a meta-analysis Tzellos TG, Toulis KA, Goulis DG, Papazisis G, Zampeli VA, Vakfari A, Kouvelas D CRD summary The authors concluded that pregabalin, at a dose of 450mg daily, was most likely to be effective (...) in treating patients with fibromyalgia, but adverse events were not negligible. Further evidence was necessary to clarify these conclusions. Given the unclear quality of included trials, the authors' cautious conclusion and recommendations for further research seem reasonable. Authors' objectives To evaluate the efficacy and safety/tolerability of gabapentin and pregabalin for treating patients with fibromyalgia. Searching PubMed, EMBASE, PsycINFO, Web of Science, CINAHL, and Cochrane Central Register

DARE.2010

54. Pregabalin, the lidocaine plaster and duloxetine in patients with refractory neuropathic pain: a systematic review

Pregabalin, the lidocaine plaster and duloxetine in patients with refractory neuropathic pain: a systematic review Pregabalin, the lidocaine plaster and duloxetine in patients with refractory neuropathic pain: a systematic review Pregabalin, the lidocaine plaster and duloxetine in patients with refractory neuropathic pain: a systematic review Plested M, Budhia S, Gabriel Z CRD summary This review found little evidence available on the treatment of refractory neuropathic pain with pregabalin (...) , lidocaine plasters and duloxetine. The authors' cautious conclusions regarding the evidence from the uncontrolled studies in the review are likely to be reliable. Authors' objectives To assess the efficacy, safety and tolerability of pregabalin, lidocaine plasters and duloxetine in patients with refractory neuropathic pain. Searching MEDLINE, EMBASE and Cochrane Central Register of Controlled Trials (CENTRAL) were searched from January 1998 to December 2008 for relevant studies published in English

DARE.2010

55. Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome

Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome Hauser W, Petzke F, Sommer C CRD summary The authors concluded that there was evidence of the short-term (up to six months) efficacy of duloxetine, milnacipran and pregabalin in fibromyalgia syndrome (...) ; the drugs differed in their effects on fibromyalgia syndrome domains and side-effects. The conclusions about the relative efficacy of drugs were not based on direct comparisons and may not be definitive. Authors' objectives To compare the efficacy and side-effects of duloxetine, milnacipran and pregabalin for the treatment of fibromyalgia syndrome. Searching MEDLINE, SCOPUS and Cochrane Central Register of Controlled Trials (CENTRAL) were searched to May 2009. Information was provided about the search

DARE.2010

56. Cost effectiveness of pregabalin in the treatment of fibromyalgia from a UK perspective

Cost effectiveness of pregabalin in the treatment of fibromyalgia from a UK perspective Cost effectiveness of pregabalin in the treatment of fibromyalgia from a UK perspective Cost effectiveness of pregabalin in the treatment of fibromyalgia from a UK perspective Choy E, Richards S, Bowrin K, Watson P, Lloyd A, Sadosky A, Zlateva G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of pregabalin versus placebo, duloxetine, gabapentin, tramadol, or amitriptyline, for the treatment of fibromyalgia. Pregabalin 450mg was consistently more cost-effective than pregabalin 300mg and both doses were cost-effective over placebo and duloxetine, for a population with severe disease. The study

NHS Economic Evaluation Database.2010

57. Cost effectiveness of a lidocaine 5% medicated plaster compared with pregabalin for the treatment of postherpetic neuralgia in the UK: a Markov model analysis

Cost effectiveness of a lidocaine 5% medicated plaster compared with pregabalin for the treatment of postherpetic neuralgia in the UK: a Markov model analysis Cost effectiveness of a lidocaine 5% medicated plaster compared with pregabalin for the treatment of postherpetic neuralgia in the UK: a Markov model analysis Cost effectiveness of a lidocaine 5% medicated plaster compared with pregabalin for the treatment of postherpetic neuralgia in the UK: a Markov model analysis Ritchie M, Liedgens H (...) , Nuijten M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The aim was to evaluate the cost-effectiveness of a lidocaine plaster compared with pregabalin for postherpetic neuralgia in the UK. The authors concluded that the lidocaine plaster

NHS Economic Evaluation Database.2010

58. Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective

Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective Vera-Llonch M, Dukes E, Rejas J, Sofrygin O, Mychaskiw M, Oster G Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study compared oral pregabalin, an anticonvulsant medication, with venlafaxine extended release, for patients with generalised anxiety disorder. The authors concluded that pregabalin appeared to be cost

NHS Economic Evaluation Database.2010

59. Amitriptyline vs. pregabalin in painful diabetic neuropathy: a randomized double blind clinical trial

Amitriptyline vs. pregabalin in painful diabetic neuropathy: a randomized double blind clinical trial 19900234 2009 11 10 2010 05 11 2015 11 19 1464-5491 26 10 2009 Oct Diabetic medicine : a journal of the British Diabetic Association Diabet. Med. Amitriptyline vs. pregabalin in painful diabetic neuropathy: a randomized double blind clinical trial. 1019-26 10.1111/j.1464-5491.2009.02806.x To compare the efficacy and safety of pregabalin and amitriptyline in alleviating pain associated (...) with diabetic peripheral neuropathy. A randomized, double-blind, crossover, active-control, clinical trial with variable dose titration was carried out (n = 51). Amitriptyline orally, at doses of 10, 25 and 50 mg at night-time and pregabalin orally, at doses of 75, 150 and 300 mg twice daily, by optional titration was used. Each drug treatment was of 5 weeks. There was a placebo washout period for 3 weeks between the two drugs. Assessment for pain relief, overall improvement and adverse events were carried

EvidenceUpdates2010

60. Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: findings from a cost-consequences analysis in a nested case-control study

Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: findings from a cost-consequences analysis in a nested case-control study Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: findings from a cost-consequences analysis in a nested case-control study Pregabalin and gabapentin in matched patients with peripheral neuropathic pain (...) was to assess the costs and benefits of pregabalin and gabapentin, for the treatment of adults with peripheral neuropathic pain, in routine medical practice. The authors concluded that pregabalin seemed to reduce the mean weekly intensity of pain more than gabapentin, with no significant difference in costs. The reporting and methods were satisfactory. The authors' conclusion appears to be appropriate, but highly uncertain. Type of economic evaluation Cost-effectiveness analysis, cost-utility analysis Study

NHS Economic Evaluation Database.2010